158 results about "Ion binding" patented technology

Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The invention relates to a browning conditioning fluid containing sulfydryl compound. The browning conditioning fluid is the solution which is used for improving the bonding force between an inner-layer copper surface and a prepreg sheet and also can improve the copper loading amount of the browning conditioning fluid in the production and manufacture technology of the multilayer board of a printed circuit board (PCB). The browning conditioning fluid comprises 90-120g/L of sulfuric acid, 10-20g/L of hydrogen peroxide, 10-20g/L of corrosion inhibitor, 20-50mg/L of halide ion, 1.0-4.0g/L of bonding force accelerator and the balance of water which is added until the solution is 1L, wherein the bonding force accelerator is selected from a sulfydryl-substituted nitrogen-containing heterocycle compound. The copper carrying amount of the browning liquid can reach 50g/L and can be guaranteed to be 1-50g/L. The copper surface is browned to obtain an even and rough brown surface, and the copper surface is kept to have stable and favorable bonding force with the prepreg sheet and excellent heat resistance.

The invention discloses an oxygen sensitive variable ink. The oxygen sensitive variable ink comprises the following components: an oxygen sensitive reactive dye, a reducing agent, a binder, a hydrophobic agent and an organic solvent. By adopting the binder of the variable ink, the film formation viscosity of the ink is increased; an ion binding is generated by the hydrophobic agent and the oxygen sensitive reactive dye, so that the oxygen sensitive reactive dye has a hydrophobic function; besides, the reducing agent of the variable ink can be substituted by a photocatalyst material and an electron donor material, and the variable ink is an UV activated variable ink; after being radiated by the UV light with proper wavelength, the oxygen sensitive reactive dye is re-activated by a photo electron generated by the photocatalyst material so that the oxygen sensitive reactive dye returns to a reducing state, and therefore, whether an oxidizing reaction is generated can be judged through the color change of the oxygen sensitive reactive dye in reducing state.

A novel coordination chemistry or metal ion binding approach to controlling the site-isolation and orientation of virus particles, such as TMV, on a nanoarray template generated by lithography including Dip Pen Nanolithography. By using the surface chemistry that is inherent in many viruses, metal-ion based or inorganic coordination chemistry was used to immobilize individual virus particles without the need for their genetic modification. Single particle control will enable a wide variety of studies involving viruses that are not possible with microarrays because of the size mismatch between the architecture of the virus and the features that make up such arrays. These include: single particle, single cell infectivity studies, the exploration of such structures as templates in materials synthesis and molecular electronics, and studies aimed at understanding how surface presentation can influence their bioactivity. This is a pioneering example of such control at the single-particle level, and therefore, commercial use of nanoarrays in biological systems.

The invention discloses a detecting method for divalent mercury ions. The principle for detecting mercury ions by using the method is as follows: a single-chain DNA (Deoxyribose Nucleic Acid) molecule B modified by fluorescein contains a sequence which is complementary with a sequence of a DNA catching needle (a single-chain DNA molecule A) fixed on the surface of a probe, and also contains a T-T base pair mismatch structure which can be combined with the divalent mercury ions. During detection, the single-chain DNA molecule B modified by the fluorescein and the mercury ions are simultaneously input to the surface of an optical fiber sensor probe for evanescent waves, and the divalent mercury ions are combined with the single-chain DNA molecule B modified by the fluorescein by the DNA catching needle in a competition way. The more the concentration of the divalent mercury ions is, the fewer the single-chain DNA molecule B modified by the fluorescein and combined with the DNA catching needle on the optical fiber sensor probe for evanescent waves is, so that a fluorescence intensity signal detected by an optical detecting platform for evanescent waves is weaker. An effective means is provided for the rapid on-site and real-time detection of heavy metal mercury ions in the fields of foods, medicines and environments.

The invention provides a synergistic composition useful as a nitrification inhibiting additive for ammonium producing fertilizers which comprises:(a) benzotriazole in the range of 2.5 to 50% (by wt % of the ammonium fertilizer),(b) metal chelating agent (cooper/nickel in the range from about 1 to 50% (by wt % of the ammonium) and ion binding compound and precursors and fertilizer.

Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.